We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Read MoreHide Full Article
Key Takeaways
Keytruda sales rose 7% to nearly $31.7B in 2025, driving about 55% of MRK's pharma sales.
Keytruda growth is fueled by earlier-stage uptake, metastatic indications and Keytruda Qlex launch.
MRK projects more than $70B in pipeline opportunities by mid-2030s beyond the Keytruda LOE.
Merck (MRK - Free Report) has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s pharmaceutical sales and has played an instrumental role in driving Merck’s steady revenue growth over the past few years.
Keytruda, approved for various cancer indications, recorded sales of almost $31.7 billion in 2025, up 7% year over year. Importantly, the company expects the growth to continue till Keytruda loses patent exclusivity in 2028.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications. Continued strong momentum in metastatic indications is also boosting sales growth. In 2026, the company expects Keytruda sales to continue to grow. The recent FDA approval of Keytruda and Keytruda Qlex (subcutaneous formulation of Keytruda) for the ovarian cancer indication should contribute to sales growth in 2026, as the drug previously had no approved use in this indication.
Though Keytruda intravenous (IV) is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then. Management expects Keytruda to achieve peak sales of $35 billion by 2028 before it loses exclusivity.
Building on this, Merck has been working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna, Merck is developing a personalized mRNA-based cancer vaccine, intismeran autogene (V940/mRNA-4157), in combination with Keytruda. The regimen is currently being evaluated in pivotal phase III studies for earlier-stage and adjuvant NSCLC as well as adjuvant melanoma.
Merck recently announced that it is reorganizing its Human Health segment into two focused units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. The streamlined structure is expected to enhance commercial focus and support sustainable long-term growth, particularly as Merck prepares for revenue diversification ahead of Keytruda’s eventual loss of exclusivity in 2028.
On its fourth-quarter 2025 conference call, Merck said it expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s. Management also noted that this figure ($70 billion) is more than twice the prior peak consensus sales estimate of $35 billion for Keytruda in 2028 and represents a $20 billion increase from what the company had expected just one year ago.
Merck’s latest reorganization into focused units directly supports the company’s projected $70 billion commercial opportunity by the mid-2030s. By creating dedicated leadership for Oncology and for Specialty, Pharma & Infectious Diseases, Merck can more effectively advance and launch its diversified pipeline.
PD-L1 Inhibitors Competing With MRK's Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $10.05 billion in Opdivo sales in 2025, up 8% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 3.56 billion in Tecentriq sales in 2025, up 3% year over year.
AZN’s Imfinzi generated sales of $6.06 billion in 2025, up 28%, driven by demand growth in bladder and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Key Takeaways
Merck (MRK - Free Report) has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s pharmaceutical sales and has played an instrumental role in driving Merck’s steady revenue growth over the past few years.
Keytruda, approved for various cancer indications, recorded sales of almost $31.7 billion in 2025, up 7% year over year. Importantly, the company expects the growth to continue till Keytruda loses patent exclusivity in 2028.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications. Continued strong momentum in metastatic indications is also boosting sales growth. In 2026, the company expects Keytruda sales to continue to grow. The recent FDA approval of Keytruda and Keytruda Qlex (subcutaneous formulation of Keytruda) for the ovarian cancer indication should contribute to sales growth in 2026, as the drug previously had no approved use in this indication.
Though Keytruda intravenous (IV) is set to face loss of exclusivity in 2028, its sales are expected to stay strong until then. Management expects Keytruda to achieve peak sales of $35 billion by 2028 before it loses exclusivity.
Building on this, Merck has been working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna, Merck is developing a personalized mRNA-based cancer vaccine, intismeran autogene (V940/mRNA-4157), in combination with Keytruda. The regimen is currently being evaluated in pivotal phase III studies for earlier-stage and adjuvant NSCLC as well as adjuvant melanoma.
Merck recently announced that it is reorganizing its Human Health segment into two focused units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. The streamlined structure is expected to enhance commercial focus and support sustainable long-term growth, particularly as Merck prepares for revenue diversification ahead of Keytruda’s eventual loss of exclusivity in 2028.
On its fourth-quarter 2025 conference call, Merck said it expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s. Management also noted that this figure ($70 billion) is more than twice the prior peak consensus sales estimate of $35 billion for Keytruda in 2028 and represents a $20 billion increase from what the company had expected just one year ago.
Merck’s latest reorganization into focused units directly supports the company’s projected $70 billion commercial opportunity by the mid-2030s. By creating dedicated leadership for Oncology and for Specialty, Pharma & Infectious Diseases, Merck can more effectively advance and launch its diversified pipeline.
PD-L1 Inhibitors Competing With MRK's Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $10.05 billion in Opdivo sales in 2025, up 8% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 3.56 billion in Tecentriq sales in 2025, up 3% year over year.
AZN’s Imfinzi generated sales of $6.06 billion in 2025, up 28%, driven by demand growth in bladder and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.